Psychedelic Research Papers

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder
In this open label study (n=24) depressed patients were given psilocybin (25mg/70kg) and the effects of psilocybin therapy on cognitive flexibility, neural flexibility and neurometabolite concentrations were assessed. While it was found that depressive symptoms were reduced, interestingly, it was also found that increased dynamics of functional connectivity (dFC) between the anterior and posterior cingulate cortices (ACC/PCC) predicted improvements in cognitive flexibility. These findings suggest a nuanced relationship between cognitive and neural flexibility.
Translational Psychiatry
November 2021
Cited by 0
Psychedelic Cognition—The Unreached Frontier of Psychedelic Science
This paper (2022) reviews the current state of research regarding the effect psychedelics have on different aspects of cognition. The gaps regarding the acute effects psychedelics have on cognition are discussed as well as the findings related to how psychedelics impact memory, attention, reasoning, social cognition, and creativity.
Frontiers in Neuroscience
March 2022
Cited by 0
Chemical cousins with contrasting behavioural profiles: MDMA users and methamphetamine users differ in social-cognitive functions and aggression
This comparative study (n=165) evaluated social cognitive functions and behaviors in chronic METH users, chronic MDMA users, and stimulant-naïve controls. METH users exhibited diminished cognitive and emotional empathy towards positive stimuli, elevated punitive social behavior regardless of provocation, and heightened trait anger. MDMA users showed a distinct rise in punitive behavior when provoked, with correlations suggesting associations between substance use patterns and social-cognitive deficits.
European Neuropsychopharmacology
April 2024
Cited by 0
Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation
This study (n=86) assessed the effects of six infusions of ketamine (35mg/70kg) over 2 weeks on suicidality in patients with depression. Next to the Beck Scale for Suicide Ideation (SSI) and the Montgomery-Asberg Depression Rating Scale (MADRS), the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery was also used. MADRS total score and processing speed (but not other cognitive domains) were significant partial mediators of the association between ketamine treatment and improvements in suicidal ideation.
Frontiers in Psychiatry
May 2022
Cited by 0
Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers.
This study (n=48) investigates the ‘afterglow’ effects of ayahuasca, focusing on improved mindfulness and cognitive flexibility to study its psychological mechanisms using Five Facets Mindfulness Questionnaire (FFMQ), Experiences Questionnaire (EQ), Cognitive Flexibility Scale (CFS), Wisconsin Picture Card Sorting Task (WPCST) and Stroop tests. The study findings reported that further changes in cognitive flexibility in the ‘afterglow’ period do occur and also supports the therapeutic potential of ayahuasca to improve mindfulness for naïve and experienced ayahuasca users.
January 2020
Cited by 10
Differences in personality, cognitive abilities, illicit drug use, and white matter structural integrity between hallucinogen users and matched controls
This pre-print (n=106) investigated the association between hallucinogen use, macroscale brain structure, personality, cognitive ability, and illicit drug use in a naturalistic sample. Hallucinogen users scored higher on measures of openness to new experiences, and cognitive ability, and had a greater density of structural connectivity in white matter tracts that are thought to support cognition, emotion, and creativity.
Research Square
April 2022
Cited by 0
Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder
This open-label study (n=58) compared the effects of a single dose of ketamine (35-56.7mg/70kg) on the cognitive effects of those suffering from depression (MDD; n=14) or PTSD (n=15) and healthy control subjects (n=29). The study found acute declines in attention, executive function, and verbal memory. Only the effect on attention was larger in the patient groups. The baseline cognitive function of participants didn't predict clinical outcomes.
Translational Psychiatry
April 2021
Cited by 0
Psilocybin’s effects on cognition and creativity: A scoping review
This review (s=42 studies) offers an overview of the effects of psilocybin on cognition and creativity. It was found that shortly after the intake of psilocybin, cognition and creativity are impaired, especially with higher doses, but these effects diminish over time and some positive effects may emerge.
Journal of Psychopharmacology
July 2023
Cited by 0
The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality
In this study, subjects with unipolar (n=84) and bipolar (n=27) depression experiencing treatment resistance or suicidality received six infusions of ketamine (35mg/70kg) over a 12-day period. It was found that ketamine has a pro-cognitive effect on processing speed and that this effect may be independent of ketamine's effect on mood. The clinical outcomes related to ketamine may be partly mediated by improvements in cognition.
Journal of Psychiatric Research
October 2021
Cited by 2
Modulation of Social Cognition via Hallucinogens and “Entactogens”
This literature review (2019) discusses controlled experimental studies on the effects of psychedelics (e.g. LSD, psilocybin, MDMA) on social cognition and behavior to treat disorders characterized by social dysfunctions such as depression, post-traumatic stress disorder (PTSD), anxiety, and autism spectrum disorders (ASD). It also discusses persisting knowledge gaps into sex-specific drug effects and objective data on social behavior within the framework of MDMA- and hallucinogen-assisted therapy. The study suggests hallucinogen-based treatment methods and the development of novel medication for trans-diagnostic dysfunction in social cognition and noted that entactogens and hallucinogens have consistently shown prosocial effects and have identified alterations in social processing and behavior as major factors for the efficacy of treatments involving them.
Frontiers in Psychiatry
December 2019
Cited by 10
Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity
This double-blind placebo-controlled preprint study (n=34) assessed the effects of microdosing psilocybin (0.5g dried mushrooms, about 0.9mg psilocybin) on subjective experience, behaviour, creativity, perception, cognition, and brain activity. Participants received two doses (psilocybin/placebo) administered separately, one week apart. Subjective effects were more intense for the active dose, while null effects or a trend towards cognitive impairment were observed. Expectation effects may be, in part, responsible for the anecdotal benefits of microdosing.
Translational Psychiatry
August 2022
Cited by 1
Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers
This double-blind placebo-controlled cross-over study (n=20) found that psilocybin (18.2mg/70kg) disrupted certain auditory-related brain signals (P300, not MMN) which decreased in amplitude in correlation with higher psilocin serum levels (and more intense psychedelic experiences).
January 2018
Cited by 12
LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility
This trial (n=24) investigated the effects LSD (50 μg) has on cognition in healthy volunteers. It was found that LSD sub-acutely improved visuospatial memory and phonological verbal fluency and impaired cognitive flexibility when compared to placebo.
European Neuropsychopharmacology
February 2022
Cited by 0
Psychological and cognitive effects of long-term peyote use among Native Americans
This correlational study (n=176) investigated the long-term residual psychological and cognitive effects of peyote use amongst native American Church members, compared between regular users (n=61), minimal users (n=79), and members with a history of alcohol dependence (n=36). Only members with prior alcohol dependence showed neuropsychological deficits, but there was no link between psychological or cognitive deficits linked to peyote use.
Biological Psychiatry
October 2005
Cited by 169
Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial
This randomized-controlled trial (n=51) assessed the short-term effects of three subanesthetic esketamine infusions (17.5mg/70kg) in adolescents aged 13–18 with major depressive disorder (MDD) and suicidal ideation. The study found a significant improvement in processing speed and working memory in the esketamine group from baseline to days 6 and 12, with no harm to cognition observed. However, there was no significant association between baseline cognition and the antidepressant or antisuicidal effects of esketamine.
Child and Adolescent Psychiatry
September 2023
Cited by 0
The effect of ketamine on cognition, anxiety, and social functioning in adults with psychiatric disorders: A systematic review and meta-analysis
This meta-analysis (n=1,298) explored the effects ketamine has on cognition, anxiety, quality of life, and social functioning in adults with psychiatric disorders. Ketamine was found to have positive effects on depression, anxiety and social functioning but not with respect to cognition and quality of life.
Frontiers in Neuroscience
November 2022
Cited by 0
Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users
This observational, cross-sectional study (n=48) investigates the influence of ritualistic ayahuasca consumption on cognition among experienced (n=16) and beginner (n=16) ayahuasca users and a control group (n=16). It finds no evidence of cognitive decline among ayahuasca users, with experienced users showing higher scores in tasks assessing working verbal and visuospatial memories compared to beginners.
European Archives of Psychiatry and Clinical Neuroscience
May 2024
Cited by 0
Acute effects of ketamine and esketamine on cognition in healthy subjects: A meta-analysis
This meta-analysis assessed the effects of ketamine administration in healthy participants (n=1,041) on several cognitive domains. Deficits in verbal learning/memory were most prominent, whereas response inhibition was the least affected. Negative effects were dependent on infusion dose and plasma level but unaffected by enantiomer type, route of administration, sex or age.
Progress in Neuro-Psychopharmacology and Biological Psychiatry
May 2022
Cited by 0
Microdosing psychedelics has no impact on cognitive function in naturalistic settings
This observational within-subjects study (n=17) repeatedly assessed participants during their psychedelic microdosing regimen using the CNSVS neurocognitive battery in a naturalistic setting. Results indicate that neither the day of microdosing nor the day after showed significant links to enhanced or diminished performance across various cognitive functions. The study concludes that microdosing psychedelics might influence psychological pathways rather than neurocognitive ones, leading to a subjective feeling of performance enhancement.
Journal of Clinical Psychiatry
August 2023
Cited by 0
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition
This double-blind, placebo-controlled study (n=20) with psilocybin (10, 20, 30mg/70kg) and DMX (400mg/70kg) finds no global cognitive impairment. The study does find (for both drugs) effects on psychomotor performance, working memory, episodic memory, associative learning, and visual perception.
Journal of Psychopharmacology
July 2018
Cited by 61
Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism
In this study in mice, a deficiency in mGluR2 function (receptor for the neurotransmitter glutamate) was identified as a common mechanism for increased alcohol-seeking behaviour and impaired cognitive flexibility in rodent models of alcohol use disorder (AUD). Psilocybin was shown to restore prefrontal mGluR2 levels and reduce relapse behaviour. Researchers suggest a biomarker approach to target this neuronal mechanism, implying that psilocybin can treat AUD physiologically as well as psychologically, as other research has suggested.
Academic Psychiatry
November 2021
Cited by 0
Neurological and cognitive alterations induced by MDMA in humans
This preprint review (2021) surveys the literature on cognition and neuroimaging studies that have investigated functional and structural changes associated with MDMA use. It concludes that the neurocognitive/neurophysiological changes that occur with repeated MDMA use are potentially reversible over time.
Experimental Neurology
October 2021
Cited by 0
Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia
This study (n=18) used psilocybin administration in order to investigate the neuropharmacology of schizophrenia. The authors suggest that 5-HT2A and NMDA receptors may be involved in the cognitive deficits observed in schizophrenic individuals.
December 2003
Cited by 135
Psychedelics and cognitive liberty: Reimagining drug policy through the prism of human rights
This legal commentary (2016) advocates for drug-policy reform on the grounds of a liberal rights-based approach that invokes the notion of cognitive liberty as a crucial component of freedom of thought, enshrined within Article 9 of the European Convention on Human Rights (ECHR). On this basis, it is proposed that drug policy should move beyond harm-reduction strategies and calling for exemptions from criminalization on therapeutic or religious grounds, and establish a right to control one’s own consciousness via psychoactive substances, and apply policies that maximize their benefits.
International Journal of Drug Policy
January 2016
Cited by 22
Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example
This case study (n=2) describes the treatment methodology of MDMA (112.5mg) -assisted Cognitive-Behavioral Conjoint Therapy administered to a PTSD patient in conjunction with his romantic partner. Through the therapeutic context, set, and setting that entailed multiple days of participant engagement and the empathy-inducing effects of the MDMA, the procedure created strong therapeutic bonds between the couple and the therapists and facilitated the resolution of PTSD symptoms and improvement in relationship satisfaction.
Journal of Psychoactive Drugs
March 2019
Cited by 18
Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans
In this randomized, double-blind study (n=5) the MDMA like drug (S)-MDE and (R)-MDE were tested for their effect on mood, cognition and brain activity.
August 2001
Cited by 66
Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default
This paper (2022) explores historical and sociological influences on current psychedelic administration in mainstream European and American clinical research settings. It considers these dynamics in relation to cognitive-behavioural therapies (CBT) and acceptance and commitment therapy (ACT). The paper advocates for CBTs for several reasons, such as the large base of empirical evidence they have. Several types of CBTs are discussed and how they can be used to inform the preparation, session, and integration phases of psychedelic psychotherapy.
Frontiers in Psychology
May 2022
Cited by 0
Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
This rat model of Fragile X syndrome (FXS, genetic cause of autism - ASD) finds that microdoses of psilocybin normalise cognitive performance in an object recognition test.
December 2022
Cited by 0
Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression
This survey study (n=803) assessed the credibility rating of cognitive-behavioural therapy (CBT) and psilocybin-assisted therapy (PAT) among individuals reporting depressive symptoms. CBT was rated as more credible than PAT, while men and lifetime psychedelic users rated PAT more credible than women and non-users with few other predictors accounting for variance in credibility.
Journal of Psychoactive Drugs
January 2022
Cited by 0
Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition
This open-label study (n=25) explored the effects of using intravenous ketamine to treat treatment-resistant depression (TRD) in participants over the age of 60. Depressive symptoms improved significantly, 48% of participants responded, and during the acute phase, executive function measures and the fluid cognition composite score improved (Cohen's d = 0.61).
American Academy of Clinical Psychiatrists
December 2022
Cited by 0

Find Psychedelic Papers

Find all relevant psychedelic research papers in our ever-growing database. Here we cover and connect the latest research and seminal papers. From early open-label psychedelic studies with healthy volunteers to large-scale double-blind, placebo-controlled trials.

We have not only indexed over 2000 papers but have added additional contexts such as type of study, a compound studied, which paper it’s related to, the trial associated with a study, and over 30 more variables.

More coverage of psychedelic research can be found on our Research page.